Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant

Just Received European Green Light For Skin Disorder

It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.  

Scratching
Atopic dermatitis is a potentially lucrative market for Lilly • Source: Shutterstock

Days after Olumiant became the first JAK inhibitor to be approved in Europe for atopic dermatitis,Eli Lilly and Company and partner Incyte Corporation have presented more positive data on the drug for the skin disease and highlighted its potential as a treatment for alopecia.

The US giant gave little fanfare to the European Commission's approval last week for Olumiant (baricitinib) for the treatment of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.